

**Individual Patient Expanded Access
Investigational New Drug Application (IND)**
(Title 21, Code of Federal Regulations (CFR) Part 312)

Form Approved: OMB No. 0910-0814

Expiration Date: October 31, 2026

See PRA Statement on last page.

1. Physician Name, Name of Institution or Clinical Practice, Address, and Contact Information

Physician Name (<i>Sponsor</i>)		Email Address of Physician
Name of Institution or Clinical Practice		
Address 1 (<i>Street address, No P.O. boxes</i>)		
Address 2 (<i>Apartment, suite, unit, building, floor, etc.</i>)		Telephone Number of Physician
City	State	Facsimile (FAX) Number of Physician
ZIP Code		

2. Patient's Initials

3. Date of Submission (*mm/dd/yyyy*)

4. Type of Submission

NOTE: Checking box 4a or 4b will "turn on" ONLY the fields that must be completed.

4.a. Initial Submission

- ☐ Select this box if this form is an initial submission for an individual patient expanded access IND, enter the Physician's IND Number, if previously issued by FDA, and complete only fields 5 through 8, and fields 10 and 11.

4.b. Follow-Up Submission

- ☐ Select this box if this form accompanies a follow-up submission to an existing individual patient expanded access IND, and complete the items to the right in this section, and fields 9 through 11.

Investigational Drug Name

Physician's IND Number (*if known*)

5. Clinical Information

Indication

Brief Clinical History (*Patient's age, sex, weight, allergies or sensitivities, race and ethnicity (optional), diagnosis, prior therapy, response to prior therapy, reason for request, including an explanation of why the patient lacks other therapeutic options*)

Ethnicity (*check one*)

Race (*check all that apply*)

☐ Hispanic/Latino

☐ American Indian/Alaska Native

☐ Asian

☐ Not Hispanic/Latino

☐ Black or African American

☐ Native Hawaiian/Other Pacific Islander

☐ White

6. Treatment Information**Investigational Drug Name**

Name of the entity that will supply the drug (*generally the manufacturer*)

FDA Review Division (*if known*)

Treatment Plan (*Including the dose, route and schedule of administration, planned duration, and monitoring procedures. Also include modifications to the treatment plan in the event of toxicity.*)

7. Letter of Authorization (LOA), if applicable (*generally obtained from the manufacturer of the drug*)☐ I have attached the LOA. (*Attach the LOA; if electronic, use normal PDF functions for file attachments.*)**Note:** If there is no LOA, consult the Form Instructions.

8. Physician's Qualification Statement (*Including medical school attended, year of graduation, medical specialty, state medical license number, current employment, and job title. Alternatively, attach the first few pages of physician's curriculum vitae (CV), provided they contain this information. If attaching the CV electronically, use normal PDF functions for file attachments.*)

9. Contents of Submission

This submission contains the following materials, which are attached to this form (select all that apply). If none of the following apply to the follow-up communications, use Form FDA 1571 for your submission.

- | | |
|---|--|
| ☐ Initial Written IND Safety Report | ☐ Change in Treatment Plan |
| ☐ Follow-up to a Written IND Safety Report | ☐ General Correspondence |
| ☐ Annual Report | ☐ Response to FDA Request for Information |
| ☐ Summary of Expanded Access Use (treatment completed) | ☐ Response to Clinical Hold |
| ☐ Request for Withdrawal | |

10.a. Request for Authorization to Use Form FDA 3926☐ I request authorization to submit this Form FDA 3926 to comply with FDA's requirements for an individual patient expanded access IND.**10.b. Request for Authorization to Use Alternative IRB Review Procedures**☐ I request authorization to obtain concurrence by the Institutional Review Board (IRB) chairperson or by a designated IRB member, before the treatment use begins, in order to comply with FDA's requirements for IRB review and approval. This concurrence would be in lieu of review and approval at a convened IRB meeting at which a majority of the members are present.

11. Certification Statement: I will not begin treatment until 30 days after FDA's receipt of a completed application and all required materials unless I receive earlier notification from FDA that treatment may begin. I also agree not to begin or continue clinical investigations covered by the IND if those studies are placed on clinical hold. I also certify that I will obtain informed consent, and that an Institutional Review Board (IRB) will be responsible for initial and continuing review and approval of this treatment use, consistent with applicable FDA requirements. I understand that in the case of an emergency request, treatment may begin without prior IRB approval, provided the IRB is notified of the emergency treatment within 5 working days of treatment. I agree to conduct the investigation in accordance with all other applicable regulatory requirements.

WARNING: A willfully false statement is a criminal offense (U.S.C. Title 18, Sec. 1001).

Signature of Physician To enable the signature field, please fill out all prior required fields. For a list of required fields which have not yet been filled out, please click here.	Date
---	-------------

Information on where and how to submit this form is available at [Expanded Access – How to Submit](#)

For FDA Use Only		
Date of FDA Receipt	Is this an emergency individual patient IND? ☐ Yes ☐ No	Is this indication for a rare disease (prevalence < 200,000 in the U.S.)? ☐ Yes ☐ No
IND Number		

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 45 minutes per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Operations
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."